Advertisement

Topics

Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines

07:15 EDT 19 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Healthy volunteers study initiated for SYNB1020, a Synthetic Biotic™ medicine for the treatment of hyperammonemia – Synlogic™ has dosed the first subject in a Phase 1 healthy volunteers study designed to ...

Other Sources for this Article

MEDIA:
Synlogic
Courtney Heath, 617-872-2462
courtney@scientpr.com
or
INVESTORS:
Synlogic
Elizabeth Wolffe, Ph.D., 510-710-8767
liz@synlogictx.com
or
Stern IR, Inc.
Christina Tartaglia, 212-362-1200
christina@sternir.com

NEXT ARTICLE

More From BioPortfolio on "Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...